27th Pharmacovigilance 2022
“Latest developments in pharmacovigilance, drug safety and risk management”
23rd & 24th February 2022, Pestana Chelsea Bridge Hotel London, UK
After the successful journey of a series of 26 Pharmacovigilance conferences, Virtue Insight is proud to announce its 27th Pharmacovigilance 2022. We have been delivering the conference through close collaboration with the industry leaders for more than a decade. For the 2022 edition, the agenda includes a host of new and exciting features focusing on how the industry should evolve especially after the pandemic. Take a chance and make it count by attending our event to network with your peers, exchange expertise and experiences, and arm yourself with the latest information to take your department to the next level.
SPONSORS:
BRONZE SPONSOR - ProPharma Group
ASSOCIATE SPONSOR - Brookwood
DELEGATE REGISTRATION:
Email - [email protected] or TEL: +44-20 3509 3779
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.
Super Early Discount - Valid till 06th December 2021
1 Delegate @ £699+20% VAT
3 Delegates @ £1,398+20% VAT
Early Discount - Valid till 20th January 2022
1 Delegate @ £999+20% VAT
3 Delegates @ £1,998+20% VAT
Standard Pricing - From 21st January 2022
1 Delegate @ £1,299+20% VAT
3 Delegates @ £2,598+20% VAT
Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to [email protected]
KEY SPEAKERS:
KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen (USA)
SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda Pharmaceuticals
FABIO DE GREGORIO, Vice President, Head of Drug Safety Europe, EU QPPV, Shionogi Europe
MOHAMED ABDILLAHI, Director, Risk management Product Lead, Pfizer
WIVINA DE WAELE, Director EMEA, Global Drug Safety, Alexion Pharmaceuticals
RISHI CHOPRA, Senior Director, Head of International PV | Deputy EU UK QPPV, Biogen
JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi
JAMES WHITEHEAD, Director and Team Lead - Patient Safety Medical Devices & Digital Health, AstraZeneca
KLAUDIJA MARIJANOVIC BARAC, Sr. Director, Global Patient Safety & PV - TPC, Teva
MARIA MADDALENA LINO, Safety Risk Lead Director, Pfizer
PAV RISHIRAJ, Director (UK QPPV), Head of Patient Safety – UK and Ireland & ABPI PV Expert Chair, Merck
MIRCEA CIUCA, Global Therapeutic Area Head - Global Clinical Safety & PV, CSL Behring
RAJ BHOGAL, Senior Director, R&D Audits & Inspections, Jazz Pharmaceuticals
VALENTINA MANCINI, Director PV, EU QPPV, Shionogi
TEA BABIC, Assoc. Dir – Audits and Inspections, Teva
SHAANTANU DONDE, Head of Portfolio Management Team - Medical Affairs, Viatris
UWE GUDAT, Head of Medical Affairs & CSPV, Fresenius Kabi
RICARDA TIEMEYER, Associate Director Head of Pharmacovigilance, Biogen
HOWARD SNOW, VP, Head of Pharmacovigilance, Hengrui Therapeutics
WALLY LANDSBERG, Vice President, Global Head of Medical Safety, Kyowa Kirin
RANJANA KHANNA, Director & Head Pharmacovigilance Quality Assurance, Vifor Pharma
YVONNE NANCIU, Country Head Pharmacovigilance, Bayer
ALESSANDRO VAGHEGGINI, Associate Principal Biostatistician, Clinical Safety Statistics, MSD (CH)
AMGAD SHEBL, Director, Global Clinical Safety & PV / Clinical R&D, CSL Behring
RUDI SCHEERLINCK, Executive Director Safety Evaluation & Risk Management, Galderma
ALINA TU DOR, Senior Director, Pharmacovigilance, Kyowa Kirin International
PHILIP OLUWOLE, PFO PV Consulting
FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead - Compliance & Regulatory Affairs, Novartis
DIMITRIS ZAMPATIS, Head of Pharmacovigilance EMEA-EEA QPPV, Lupin
MINHAJ OBEIDULLAH, Head Compliance & Risk Management, Novartis
CHETAN SHATAPATHY, Consultant Medical Advisor, Office of the (QPPV) (Interim), Janssen Pharmaceutical
JEAN-KILGOUR CHRISTIE, Deputy EU QPPV, Novartis
DANIELA DI COSMO, Senior PV Manager, Global PV, Ferring Pharmaceuticals
NICOLE BAKER, Co-Founder, BioLogit
MICHAEL RAMCHARAN, Managing Director, Reumat Consulting
MARINA SUVAKOV, Global Head Safety Surveillance, Philip Morris International
SANDY EISEN, Chief Medical Officer, Frontline Pharma Consulting
ALEXANDER ROUSSANOV, International Partner, Life Sciences and Privacy, Arnold & Porter
Plus more joining soon
KEY THEMES DISCUSSED:
Rising back and getting back on track from the pandemic - Lessons learnt from the pandemic
Market analysis – Pharmacovigilance in 2022 - future horizons and efficiencies
Improving the PV ecosystem for advancement – Rising back from the pandemic
Implementation of the new EU Clinical Trial rules - and the impacts on safety departments
Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration
Documentation (RMPs, PSURs, PADERs, PBRERs)
Quality, Safety & Signal Detection – Peep into the future
Risk Management Plan and Pharmacovigilance System - New Paradigm
Pharmacovigilance Audits: Keeping on the right side of inspectors
Medical devices – Increasing safety perspective
Case studies from various countries on the PV frameworks around the world
Prioritising Patients - Reshaping patient safety
Brexit Implications for the Pharmaceutical (pharmacovigilance) Industry
New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
The developing regulatory framework in advanced and developing markets – EU, USA & ROW
Be part of a major networking opportunity
WHO SHOULD ATTEND:
CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.